Dihexa: Benefits, Dosage & FDA Status
Dihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
FDA Status
Not FDA-approved — research compound (HGF/c-Met-mimetic)
Typical Dose
8–45 mg orally daily (research-only)
Evidence Grade
CPrimarily preclinical or anecdotal
Half-Life
~10 hours (estimated)
Routes of Administration
oral, transdermal
First Synthesized
2010
Clinics Indexed
10 providers have offered Dihexa in our tracked directory.
Mechanism of Action
Activates HGF/c-Met signaling cascade, driving rapid synapse formation in hippocampus and cortex in animal models.
Key Reported Benefits
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C indicates primarily preclinical or anecdotal.
Reported Side Effects
- •Limited human safety data
Contraindications
- ⚠Pregnancy
- ⚠Active malignancy (HGF/c-Met involvement)
Regulatory & Safety Context
FDA status: Not FDA-approved — research compound (HGF/c-Met-mimetic)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on Dihexa. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
Semax
BA synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
Cerebrolysin
BA standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.
Selank
BA synthetic analog of tuftsin with anxiolytic and nootropic properties. Modulates GABA and serotonin systems to reduce anxiety without sedation.
DSIP
CA nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
ARA-290
BAn 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
Pinealon
CA short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.